newsfilter
← Latest News
GlobeNewswire·

Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments

Highly differentiated immunotherapy for celiac disease (VTP-1000) in the clinic, with Phase 1 single ascending dose readout from AVALON expected in the third quarter of 2025;Initiation of VTP-1000 multiple ascending dose